High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas

Tissue Antigens

Volumn 52, Issue 2, 1998, Pages 114-123

  Cabrera, T ^a   Collado, A ^a   Fernandez, M A ^a   Ferron, A ^a   Sancho, J ^b   Ruiz Cabello, F ^a   Garrido, F ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

Alleles; Class I; Colon; HLA; Tumor

Indexed keywords

CD3 ANTIGEN; HLA ANTIGEN CLASS 1; MONOCLONAL ANTIBODY;

ANTIGEN EXPRESSION; ARTICLE; COLORECTAL CARCINOMA; GENE LOCUS; HUMAN; MAJOR CLINICAL STUDY; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 0031856709     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0039.1998.tb02274.x     Document Type: Article

References (29)

1. Carrido F, Cabrera T, Lopez-Nevot MA, Ruiz-Cabello F. HLA class I antigens in human tumors. Adv Cancer Res 1995: 67: 155-95.
2. Concha A, Cabrera T, Ruiz-Cabello F, Garrido F. Can the HLA phenotype be used as a prognostic factor in breast carcinomas? Int J Cancer 1991: 6 Suppl: 146-54.
3. Gutierrez J, Lopez-Nevot MA, Cabrera T et al. Class I and II HLA antigen distribution in normal mucosa, adenoma and colon carcinoma: relation with malignancy and invasiveness. Exp Clin Immunogenet 1987: 4: 144-52.
4. Momburg F, Möller P, Moldenhauer G, Hämmerling GJ. Loss of HLA-A,B,C in colorectal carcinoma is related to the degree of differentiation. J Immunogenet 1986: 13: 195-9.
5. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern P. Natural history of HLA antigens during tumor development. Immunol Today 1993: 14: 491-9.
6. Browning MJ, Krausa P, Rowan A et al. Loss of human leukocyte antigen expression on colorectal tumor cell lines: implications for anti tumor immunity and immunotherapy. J Immunother 1993: 14: 163-71.
7. Cabrera T, Fernandez MA, Sierra A et al. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol 1996: 50: 127-34.
8. Garrido F, Ruiz-Cabello F, Cabrera T et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol Today 1997: 18: 89-95.
9. Garrido F, Cabrera T, Accolla RS et al. HLA and cancer. In: Charron D, ed. HLA. Genetic diversity of HLA. Functional and medical implications. Vol I. Paris: EDK, 1997: 445-52.
10. Barnstable CJ, Bodmer WF, Brown G et al. Production of monoclonal antibodies to group A erythrocytes HLA and other human cell surface antigens new tool for genetic analysis. Cell 1978: 14: 9-20.
11. Lopez-Nevot MA, Cabrera T, de la Higuera B, Ruiz-Cabello F, Garrido F. Production and characterization of monoclonal antibodies against leukemic cells. Immunologia 1986: 5: 51-9.
12. Spear BT, Kornbluth J, Strominger JL, Wilson DB. Evidence for a shared HLA-A intralocus determinant defined by monoclonal antibody 131. J Exp Med 1985: 162: 1802-10.
13. 1 domain of HLA-A molecules. Immunogenetics 1989: 30: 50-3.
14. Burrone OR, Fefford RF, Gilmore D, Milstein C. Stimulation of HLA ABC by IFN. The derivation of Molt 4 variant and the differential expression of HLA ABC subset. EMBOJ 1985: 4: 2855-60.
15. Setini A, Beretta A, De Santis C et al. Distinctive features of the alpha 1-domain alpha helix of HLA-C heavy chains free of beta 2-microglobulin. Hum Immunol 1996: 46: 69-81.
16. 2-microglobulin: differential effects of inhibition of glycosylation on class I subunit association. Eur J Immunol 1988: 18: 801-8.
17. Robbins PF, Kawakami Y. Human tumor antigens recognized by T cells. Curr Opin Immunol 1996: 8: 628-36.
18. Marchand M, Weynants P, Rankin E et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995: 63: 883-5.
19. Keating PJ, Cromm FV, Duggan-Keen M et al. Frequency of down regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 1995: 72: 405-11.
20. Esteban F, Concha A, Huelin C et al. Histocompatibility antigens in primary and metastatic squamous cell carcinoma of the larynx. Int J Cancer 1989: 43: 436-12.
21. Esteban F, Redondo M, Delgado M, Garrido F, Ruiz-Cabello F. MHC class I antigens and tumour-infiltrating leucocytes in laryngeal cancer: long-term follow-up. Br J Cancer 1996: 74: 1801-4.
22. Wang Q, Stanley J, Kudoh S et al. T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present. J Immunol 1995: 155: 1382-92.
23. lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993: 53: 5613-16.
24. Ghosh P, Sica A, Young HA et al. Alterations in NFkB/Rel family proteins is splenic T-cells from tumor-bearing mice and reversal following therapy. Cancer Res 1994: 54: 2969-72.
25. 2m gene expression. J Clin Invest 1991: 87: 284-92.
26. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995: 16: 487-94.
27. Browning M, Petronzelli F, Bicknell D et al. Mechanisms of loss of HLA class I expression on colorectal tumor cells. Tissue Antigens 1996: 47: 364-71.
28. 2-microglobulin mRNA in human colon carcinoma. J Exp Med 1989: 169: 309-14.
29. 2-microglobulin in HLA negative tumors. Scand J Immunol 1991: 34: 147-52.